Biotechnology
4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs , […]
Read More
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. […]
Read More
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs Jim interviewed at this week’s JPMorgan […]
Read More
CVS to close ‘select’ pharmacies in Target stores in the coming months
CVS Health plans to close select pharmacies inside Target stores early this year, a company spokesperson said Thursday, as retail pharmacy chains in the U.S. struggle to boost profits. The closures will begin in February and finish by the end of April, the spokesperson said in a statement. She added that employees affected by the […]
Read More
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment. […]
Read More
Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab. The revenue from the shots met Moderna’s forecast for the year, even as sales plummeted from the […]
Read More
Eli Lilly's direct drug sales alone may not upend the industry, but others could follow suit
Sopa Images | Lightrocket | Getty Images Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including its red-hot weight loss treatment Zepbound, to expand patient access. The company’s direct-to-consumer push announced Thursday, the first of its kind for a big drugmaker, […]
Read More
Florida wins first FDA approval to import cheaper drugs from Canada
Pharmacist Thomas Jensen, looks over a prescription drug at the Rock Canyon pharmacy in Provo, Utah, May 9, 2019. George Frey | Reuters The Food and Drug Administration on Friday approved Florida’s plan to import cheaper prescription drugs from Canada, a first-in-the-nation move that could reduce costs for Americans but faces fierce opposition from the […]
Read More
Walgreens posts earnings beat but slashes quarterly dividend nearly in half
A man walks near a Walgreens pharmacy on March 09, 2023 in New York City. Leonardo Munoz | Corbis News | Getty Images Walgreens reported fiscal first-quarter adjusted earnings and revenue that topped expectations on Thursday, but cut its quarterly dividend nearly in half. The retail pharmacy giant slashed its dividend to 25 cents per […]
Read More
Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
Artur Widak | Nurphoto | Getty Images Shares of Moderna jumped more than 15% on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock has […]
Read More